PDCD1 and cancer: The subsequent objective of preclinical and clinical research is to identify good combinations of PD-1/PD-L1 blockade and other possible treatments to mitigate toxic side effects, elicit powerful antitumor immune responses, and specifically eliminate cancer cells, transforming cancer into a curable and chronic disease.